|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic value of glypican-1 for patients with advanced pancreatic cancer following regional intra-arterial chemotherapy.
|
29963198 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Materials & methods:</b> This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer <i>in vitro</i> and <i>in vivo</i>.
|
31414945 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
ORI-GPC1-NP is a promising theranostic platform for the simultaneous diagnosis and effective treatment of pancreatic cancer.
|
30425490 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GPC-1 is a type of cell surface heparan sulfate proteoglycan, which is often highly expressed in PC.
|
29750031 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glypican-1 (GPC-1) has been recognized as biomarker of pancreatic cancer.
|
30202003 |
2018 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
In view of the importance of members of the TGF-beta family in pancreatic cancer, in the present study, the role of GPC1 in TGF-beta, BMP and activin signaling was analyzed.
|
17016645 |
2006 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It was reported that glypican-1 is strongly expressed in human pancreatic cancer, and that it may play an essential role in regulating growth-factor responsiveness in pancreatic carcinoma cells.
|
10505759 |
1999 |
|
Malignant neoplasm of pancreas
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.
|
28232049 |
2017 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
GPC1(+) crExos may serve as a potential non-invasive diagnostic and screening tool to detect early stages of pancreatic cancer to facilitate possible curative surgical therapy.
|
26106858 |
2015 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, enumeration of GPC1-positive EVs, solely or in conjunction with GP2, was unable to effectively distinguish between BPD and pancreatic cancer.
|
30800217 |
2019 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that miR-96-5p/-182-5p as good markers for PC; miR-96-5p, rather than -182-5p, inhibits GPC1 to suppress proliferation of PC cells.
|
24736782 |
2014 |
|
Malignant neoplasm of pancreas
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glypican-1 is enriched in circulating-exosomes in pancreatic cancer and correlates with tumor burden.
|
29721179 |
2018 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry of GPC1 expression in a tissue microarray of PDAC and various controls also did not demonstrate specificity of GPC1 to PDAC.
|
30800217 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
An aberrant overexpression of GPC1 protein which is usually absent in normal pancreatic duct, was a widespread marker across the full spectrum of human PDAC precursors, PDAC, and pancreatic cancerous stroma.
|
29245923 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
QRT-PCR demonstrated increased GPC1 mRNA levels in pancreatic ductal adenocarcinoma (PDAC) compared to normal pancreatic tissues (NPT), as described previously.
|
17016645 |
2006 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
GPC1-positive bead percentages determined by flow cytometry were significantly higher in PDAC than in the control group.
|
31400579 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this initial validation study, the biomarkers glypican-1 and CD63 were found to reflect the presence of PDAC and thus were used to develop a bivariate model for detecting PDAC.
|
29570265 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
However, GPC1 levels were enriched in PDAC crExos (<i>n</i> = 11), compared to the source tumors (<i>n</i> = 11; 97 ± 54 vs. 20.9 ± 12.3 pg/mL; <i>P</i> < 0.001).
|
29721179 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated that GPC1 mRNA was silenced in normal pancreata; however, it was re-expressed in PDAC tissues probably because of the promoter hypomethylation.
|
28440066 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Thus, our exosomal miR signature is superior to exosomal GPC1 or plasma CA 19-9 levels in establishing a diagnosis of PDAC and differentiating between PDAC and CP.
|
28232049 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.090 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curve (ROC) analysis showed that serum CA19-9 was significantly better than serum GPC1 in distinguishing PDAC patients from the controls (AUC, 95% CI: 0.908, 0.868-0.947 vs 0.795, 0.749-0.841, respectively).
|
30358133 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
We carried out a prospective study to quantify GPC1-positive exosomes in sera from pancreatic ductal adenocarcinoma (PDAC) patients undergoing up-front surgery, as compared to controls including patients without cancer history and patients displaying pancreatic preneoplasic lesions.
|
31400579 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Glypican-1 (GPC1) protein in exosomes was recently identified as a biomarker for the early detection of pancreatic ductal adenocarcinoma (PDAC).
|
29245923 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
|
30358133 |
2018 |